RxDoctor Payments Data

Aya Rifai, MD

Internal Medicine · Rochester Hills, MINPI 1114194958

Payments from drug & device makers

$104,923in general payments, 2019–2025

Across 491 payments — averaging $213.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$85K
  • Novo Nordisk$16K
  • Pfizer$594
  • Amgen$521
  • AbbVie$344
  • AstraZeneca$318
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$4,3754%
  • Speaking & faculty fees$81,24977%
  • Travel & lodging$10,54910%
  • Food & beverage$8,7188%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$104,923 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$29,194
Medicare patients
56
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$30,484
JanuviaSitagliptin Phosphate11$15,144
MounjaroTirzepatide14$14,123
Rosuvastatin Calcium85$1,984
Bupropion XlBupropion Hcl26$1,085
Levothyroxine Sodium45$978
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$709
Carvedilol31$584
Losartan Potassium35$480
Metoprolol Succinate13$446
Amlodipine Besylate48$395
Chlorthalidone15$343
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$319
FenofibrateFenofibrate Nanocrystallized12$316
Metformin Hcl23$298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16,025$30,48414 claims
MerckJanuvia$12$15,14411 claims
Lilly USA, LLCMounjaro$84,594$14,12314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →